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Short report
Multiple sclerosis and celiac disease: is there an increased risk?
S Salvatore*,1, S Finazzi2, A Ghezzi4, A Tosi1, A Barassi3, C Luini1, B Bettini4, A Zibetti4,
L Nespoli1 and GV Melzi d’Eril3
1Clinica Pediatrica, Universita` dell’Insubria, Varese, Italy; 2Laboratorio di Analisi, Ospedale di Legnano, Italy;
3Dipartimento di Biochimica, Universita` dell’Insubria, Varese, Italy; 4Centro Studi, Sclerosi Multipla, Ospedale di
Gallarate, Italy
Multiple sclerosis and celiac disease are both considered immune-mediated diseases. Recently, improved serological screening methods
provided a higher prevalence of celiac disease (CD) in the general population worldwide and also demonstrated gastrointestinal
symptoms may be lacking. The aim of this study was to determine the prevalence of (CD) in an unselected group of 95 adults with multiple
sclerosis using transglutaminase antibodies. No patients showed pathological values. Different immune and genetic basis between the two
diseases may represent crucial insights to explain our results.
Multiple Sclerosis (2004) 10, 711/712
Key words: multiple sclerosis; celiac disease; transglutaminase; interferon; gastrointestinal disease
Introduction
Celiac disease (CD) is a common gluten-mediated auto-
immune enteropathy with multiple extraintestinal in-
volvements.1 Different neurological manifestations have
been reported in celiac patients although the pathogenic
mechanisms are still unclear.2 Multiple sclerosis (MS) is a
complex chronic neurological disease with suspected
autoimmune pathogenesis.3 Concomitant autoimmune
diseases are reported in MS but the association of MS
with CD has not been widely explored. The aim of this
study was to establish the prevalence of CD by transglu-
taminase antibodies in a group of patients with MS.
Patients and methods
We recruited 95 consecutive adult patients (mean age 41.3
years, range 21/63 years) with MS (76 relapsing/remit-
ting, three primary-progressive and 16 secondary/
progressive MS) attending the MS outpatient follow-up
clinic. Forty-six patients were on recombinant interferon
(IFN)-b-1a treatment. IgA-tissue transglutaminase antibo-
dies (tTG) were measured by an ELISA method (EutTG,
Eurospital, Trieste, Italy).
100 mL serum (diluted 1:26) was pipetted into wells
with coated human tTG. After incubation for 60 min,
100 mL horseradish peroxidase-labelled sheep anti-human
IgA was pipetted into each well and, after a second
incubation for 60 min, 100 mL of the chromogenic sub-
strate (tetrametylbenzidine) was added. After a further
incubation for 30 min, 100 mL H2SO4 was added into each
well to cease the reaction. The optical density (OD) value
was read at 450 nm. The anti-tTG value was expressed in
arbitrary units (AU), calculated as follows:
OD sample (450 nm) 3 AU calibrator
(positive control serum)=OD calibrator (450 nm)
Normal levels of tTG were considered below 7 AU/ml in
accordance with manufacturers’ instructions. Total serum
IgA values were also determined in all subjects using an
immunoturbidometric assay (Roche Diagnostics, Milan,
Italy) and serum levels below 0.05 g/L were considered
indicative of selective IgA deficiency.
We considered the prevalence (1:174) recently reported
by Volta et al .4 in a survey of unselected normal adult
population living in North Italy as control data for
prevalence of CD. The Mann/Whitney test was employed
for statistical analysis. All patients signed informed
consent and the Ethical Committee of our hospital
approved the study.
Results
All patients presented normal values of tTG and total
serum IgA. Levels of tTG did not show any significant
correlation with MS course, disease duration or severity.
Overall, the mean level of disability in our patients was
2.5 and was 6.2, 3.4 and 2.2 in primary progressive,
secondary/progressive and relapsing/remitting patients,
respectively. Patients treated with IFN-b-1a presented
upper levels of mean tTG compared to non IFN-treated
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patients (1.1 versus 0.8 AU/ml) but without any mean-
ingful significance (P/NS). Data of patients are shown in
Table 1. No patients reported gastrointestinal symptoms or
known gastrointestinal disease.
Discussion
Immune dysregulation and impaired apoptosis are shared
findings in CD and MS supporting the hypothesis of an
increased association between the two diseases. Further-
more, neurological involvement has been reported in
CD2,5 with disappearance of symptoms for a gluten free
diet (GFD) in a proportion of early treated patients.5
Increased prevalence of autoimmune manifestations has
also been demonstrated in untreated CD1 and in treated
MS.6,7 Our patients treated with IFN-b only presented a
mild higher level of tTG but within the normal range and
without significance.
Up to now the relationship between CD and MS has
never been widely investigated. A GFD with additional
minerals and vitamins caused some clinical improvement
in a small group of MS patients without a proven CD
diagnosis.8 In two other small studies duodenal biopsies
were pathological in 3/26 total MS patients. No patients
presented gastrointestinal symptoms.9,10 In 147 patients
with different neurological manifestations2 positive anti-
gliadin antibodies (AGA) were observed in 57% of patients
but in only 35% the diagnosis of CD was confirmed. Only
1/12 patients with MS presented positive AGA but refused
the biopsy.2 The term ‘gluten sensitivity’ was thus intro-
duced to describe the presence of positive antigliadin
levels without intestinal involvement. The low specificity
of AGA for CD in neurological patients was subsequently
confirmed by other studies.11,12 The relationship between
‘gluten sensitivity’ and CD still needs to be clarified.12
Tissue transglutaminase has been recently identified as
specific auto-antigen of CD13 and nowadays represents the
most reliable diagnostic test for CD. Our study is the first
one testing CD in MS using tTG but we did not find any
positive MS patient in our population. In North Italy the
prevalence of CD has been recently estimated to be about
1:174 normal adults.4 Hence, although our sample was
small, this is the biggest study investigating CD in MS so
far. The absence of gastrointestinal symptoms in our group
cannot be considered critical for the lack of diagnosis of
CD as showed in previous reports.2,14,15
Different cytokine expression and HLA pattern (HLA-
DQ2 (DQA1*05/DQB1*02 ) or HLA-DQ8 (DQA1*03/
DQB1*0302 ) genes in CD16 versus DRB1*1501-
DQB1*0602 or DR2 in MS17) are more likely decisive in
excluding an increased CD prevalence in MS.
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Table 1 Correlation between values of transglutaminase, treat-
ment and clinical phase of MS
Clinical course of MS Patients (n) Mean values of
tTG (AU)
Total MS patients 95 0.9
IFN-treated 46 1.1
IFN-untreated 49 0.8
Relapsing-remitting 76 0.9
IFN-treated 37 1.0
IFN-untreated 39 0.8
Primary-progressive 3 1.1
IFN-treated 1 0.7
IFN-untreated 2 1.3
Secondary-progressive 16 1.1
IFN-treated 8 1.3
IFN-untreated 8 0.8
MS/multiple sclerosis; tTG/transglutaminase; AU/arbitrary
unit; IFN/interferon-b-1a.
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